[{"type": "title", "data": "CARD Non-ST Elevation Myocardial Infarction (NSTEMI) Unstable Angina (UA) Admission (Version 1.79)"}, {"type": "category", "data": "Admit/Transfer/Discharge"}, {"type": "note", "data": "Refer to Non-ST-Elevation Angina Management Algorithm"}, {"type": "note", "data": "Calculate GRACE risk score on all NSTEMI patients: GRACE ACS Risk Model Calculator"}, {"type": "category", "data": "Medications"}, {"type": "note", "data": "<P>Please ensure :&nbsp; </P><P>- loading&nbsp; dose of antiplatelets have been administered&nbsp; </P><P>- selection of a daily antiplatelet (ASA, and either ticagrelor or clopidogrel) starting day after administering loading dose </P>"}, {"type": "order", "data": "acetylsalicylic acid 81 mg oral enteric coated tablet", "value": ""}, {"type": "sentence", "data": "81 mg, PO, EC Tablet, Daily, 180 day(s)"}, {"type": "note", "data": "For patients requiring long term anticoagulation, clopidogrel is preferred&nbsp; Avoid ticagrelor in patients with severe bradycardia (heart rate less than 50 bpm) "}, {"type": "note", "data": "Hold ticagrelor or clopidogrel until after angiogram has been performed - PREFERRED"}, {"type": "order", "data": "clopidogrel", "value": ""}, {"type": "sentence", "data": "75 mg, PO, Tab, Daily, 180 day(s)"}, {"type": "note", "data": "No anticoagulation preferred if patient has a known bleeding disorder, or patient has a history of bleeding"}, {"type": "note", "data": "Ensure initial dose of anticoagulants have been administered"}, {"type": "order", "data": "Communication Order", "value": ""}, {"type": "sentence", "data": "No anticoagulation preferred, patient has a known bleeding disorder"}, {"type": "order", "data": "Communication Order", "value": ""}, {"type": "sentence", "data": "No anticoagulation preferred,  patient has a history of bleeding"}, {"type": "note", "data": "If anticoagulation required, select heparin OR enoxaparin "}, {"type": "note", "data": "Refer to Heparin Infusion Low PTT Target (Module) for heparin orders"}, {"type": "note", "data": "Enoxaparin is INDICATED for patients requiring inter-facility transfer; medically managed patients; low to moderate risk of bleeding"}, {"type": "note", "data": "Enoxaparin is CONTRAINDICATED if eGFR is less than 30 mL/min, known or suspected renal insufficiency. Use with caution if patient is over 75 years old"}, {"type": "order", "data": "enoxaparin", "value": ""}, {"type": "sentence", "data": "1 mg/kg, SubQ, Injection, q12hr(sched), 8 day(s)"}, {"type": "note", "data": "Use atorvastatin 80 mg for ACS patients"}, {"type": "order", "data": "atorvastatin", "value": "checked"}, {"type": "sentence", "data": "80 mg, PO, Tab, qHS, 180 day(s)"}, {"type": "sentence", "data": "40 mg, PO, Tab, qHS, 180 day(s)"}, {"type": "sentence", "data": "10 mg, PO, Tab, qHS, 180 day(s)"}, {"type": "order", "data": "rosuvastatin", "value": ""}, {"type": "sentence", "data": "40 mg, PO, Tab, qHS, 180 day(s)"}, {"type": "sentence", "data": "20 mg, PO, Tab, qHS, 180 day(s)"}, {"type": "sentence", "data": "10 mg, PO, Tab, qHS, 180 day(s)"}, {"type": "sentence", "data": "5 mg, PO, Tab, qHS, 180 day(s)"}, {"type": "order", "data": "rosuvastatin", "value": ""}, {"type": "sentence", "data": "40 mg, PO, Tab, qHS, 180 day(s)"}, {"type": "sentence", "data": "20 mg, PO, Tab, qHS, 180 day(s)"}, {"type": "sentence", "data": "10 mg, PO, Tab, qHS, 180 day(s)"}, {"type": "sentence", "data": "5 mg, PO, Tab, qHS, 180 day(s)"}, {"type": "note", "data": "carvedilol target dose:&nbsp; 25 mg PO BID"}, {"type": "order", "data": "carvedilol", "value": ""}, {"type": "sentence", "data": "3.125 mg, PO, Tab, BID(with meals), 180 day(s)"}, {"type": "sentence", "data": "6.25 mg, PO, Tab, BID(with meals), 180 day(s)"}, {"type": "sentence", "data": "12.5 mg, PO, Tab, BID(with meals), 180 day(s)"}, {"type": "sentence", "data": "25 mg, PO, Tab, BID(with meals), 180 day(s)"}, {"type": "sentence", "data": "50 mg, PO, Tab, BID(with meals), 180 day(s)"}, {"type": "note", "data": "bisoprolol target dose:&nbsp; 10 mg PO Daily"}, {"type": "order", "data": "bisoprolol", "value": ""}, {"type": "sentence", "data": "2.5 mg, PO, Tab, Daily, 180 day(s)"}, {"type": "sentence", "data": "1.25 mg, PO, Tab, Daily, 180 day(s)"}, {"type": "sentence", "data": "5 mg, PO, Tab, Daily, 180 day(s)"}, {"type": "sentence", "data": "10 mg, PO, Tab, Daily, 180 day(s)"}, {"type": "note", "data": "metoprolol target dose: 100 mg PO BID"}, {"type": "order", "data": "metoprolol", "value": ""}, {"type": "sentence", "data": "25 mg, PO, Tab, BID, 180 day(s)"}, {"type": "sentence", "data": "12.5 mg, PO, Tab, BID, 180 day(s)"}, {"type": "sentence", "data": "50 mg, PO, Tab, BID, 180 day(s)"}, {"type": "sentence", "data": "100 mg, PO, Tab, BID, 180 day(s)"}, {"type": "note", "data": "Re-assess therapy if serum creatinine increases by more than 30% or if serum potassium rises above 5.2 mmol/L"}, {"type": "order", "data": "ramipril", "value": ""}, {"type": "sentence", "data": "2.5 mg, PO, Cap, BID, 180 day(s)"}, {"type": "sentence", "data": "1.25 mg, PO, Cap, BID, 180 day(s)"}, {"type": "sentence", "data": "5 mg, PO, Cap, BID, 180 day(s)"}, {"type": "sentence", "data": "2.5 mg, PO, Cap, Daily, 180 day(s)"}, {"type": "sentence", "data": "5 mg, PO, Cap, Daily, 180 day(s)"}, {"type": "sentence", "data": "10 mg, PO, Cap, Daily, 180 day(s)"}, {"type": "order", "data": "perindopril", "value": ""}, {"type": "sentence", "data": "4 mg, PO, Tab, Daily, 180 day(s)"}, {"type": "sentence", "data": "2 mg, PO, Tab, Daily, 180 day(s)"}, {"type": "sentence", "data": "8 mg, PO, Tab, Daily, 180 day(s)"}, {"type": "note", "data": "Avoid combination of ACE Inhibitor with ARB "}, {"type": "note", "data": "Angiotensin Receptor Blocker (ARB) - indicated for ACE- inhibitor intolerance"}, {"type": "note", "data": "Re-assess therapy if serum creatinine increases by more than 30% or if serum potassium rises above 5.2 mmol/L"}, {"type": "order", "data": "candesartan", "value": ""}, {"type": "sentence", "data": "8 mg, PO, Tab, Daily, 180 day(s)"}, {"type": "sentence", "data": "4 mg, PO, Tab, Daily, 180 day(s)"}, {"type": "sentence", "data": "16 mg, PO, Tab, Daily, 180 day(s)"}, {"type": "sentence", "data": "32 mg, PO, Tab, Daily, 180 day(s)"}, {"type": "order", "data": "valsartan", "value": ""}, {"type": "sentence", "data": "40 mg, PO, Tab, BID, 180 day(s)"}, {"type": "sentence", "data": "80 mg, PO, Tab, BID, 180 day(s)"}, {"type": "sentence", "data": "160 mg, PO, Tab, BID, 180 day(s)"}, {"type": "order", "data": "losartan", "value": ""}, {"type": "sentence", "data": "25 mg, PO, Tab, Daily, 180 day(s)"}, {"type": "sentence", "data": "50 mg, PO, Tab, Daily, 180 day(s)"}, {"type": "sentence", "data": "75 mg, PO, Tab, Daily, 180 day(s)"}, {"type": "sentence", "data": "100 mg, PO, Tab, Daily, 180 day(s)"}, {"type": "note", "data": "Consider proton-pump inhibitor for those on dual antiplatelet therapy at high risk of bleeding, including history of GI bleed or Peptic ulcer disease, or multiple risk factors such as age greater than 65 years, concurrent oral NSAIDs, anticoagulation or corticosteroids"}, {"type": "order", "data": "pantoprazole sodium", "value": ""}, {"type": "sentence", "data": "40 mg, PO, EC Tablet, Daily, 180 day(s)"}, {"type": "note", "data": "Avoid nitroglycerin if any of the following are present:&nbsp;&nbsp; - SBP below 90 mmHg or if more than 30 mmHg drop from baseline&nbsp; - Suspected right ventricular infarction&nbsp; - Recent use of phosphodiesterase inhibitors: within 24 hours for sildenafil (VIAGRA) and vardenafil (LEVITRA), within 48 hours for tadalafil (CIALIS)"}, {"type": "order", "data": "nitroglycerin 0.4 mg sublingual spray", "value": ""}, {"type": "sentence", "data": "0.4 mg, SL, Spray, q5min, PRN, Chest pain, 3 dose(s)"}, {"type": "note", "data": "&quot;nitroglycerin titratable infusion (0.2 mg/ml) in d5w standard&quot; CIS Pharmacy to Update with IV Set When Built"}, {"type": "category", "data": "Communication Orders"}, {"type": "order", "data": "Communication Order", "value": ""}]
